Last updated: February 13, 2026
What Is the Current Market Status of NDC 42385-0945?
NDC 42385-0945 corresponds to Tucatinib (brand name: Tukysa), developed by Seattle Genetics in partnership with BeyondSpring. Approved by the FDA in April 2020 for the treatment of HER2-positive metastatic breast cancer. The drug targets advanced HER2-positive breast cancer, particularly in patients who have received trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1).
The drug's initial approval is limited, but its market potential is expanding as it gains recognition in oncology treatment protocols.
How Does NDC 42385-0945 Compare to Similar HER2-Targeted Therapies?
| Therapy |
Indication |
Approval Date |
Annual Sales (Pre-2023) |
Market Share |
Pricing (per treatment cycle) |
| Tucatinib (Tukysa) |
HER2-positive metastatic breast cancer |
April 2020 |
$300 million (2022) |
10-15% |
$10,000–$12,000 |
| Trastuzumab (Herceptin) |
HER2-positive breast cancer, gastric cancer |
1998 |
$4.2 billion (2022) |
50-60% |
$2,000–$4,000 per dose |
| Pertuzumab (Perjeta) |
HER2-positive breast cancer |
2012 |
$1.3 billion (2022) |
10-15% |
$7,000–$8,500 per cycle |
| T-DM1 (Kadcyla) |
HER2-positive metastatic breast cancer |
2013 |
$1.1 billion (2022) |
10% |
$8,000–$9,000 per cycle |
Tucatinib captures a minority market share but is seen as a complementary therapy post-trastuzumab and pertuzumab failure.
What Are the Price Trends and Key Pricing Drivers?
The pricing of NDC 42385-0945 (Tucatinib) has remained relatively stable since launch but may face pressure from biosimilars and generic options in the long-term. The current treatment cycle costs range from $10,000 to $12,000, with variations based on dosing and healthcare settings.
Factors influencing pricing include:
- Cost of development and manufacturing: being an oral kinase inhibitor, manufacturing costs are moderate.
- Market exclusivity: limited patent life post-2025.
- Therapeutic competition: introducing combination therapies and biosimilars could lower prices.
- Reimbursement policies:coverage varies across insurers, impacting net pricing.
- Clinical efficacy: high response rates in specific patient populations justify premium pricing.
What Are Future Market Projections and Growth Factors?
The oncology drug market is expected to grow at a CAGR of 8-10% through 2028, driven by increased prevalence of HER2-positive breast cancers and adoption of targeted therapies.
For tucatinib:
- Market estimates project sales reaching $500 million by 2025.
- Growth will depend on expanded indications: trials are ongoing for earlier lines of therapy and other HER2-positive cancers.
- Combination therapies involving tucatinib may stimulate demand, especially if survival benefits are confirmed.
Key factors influencing future growth include:
- Expansion into adjuvant and early-stage settings.
- Regulatory approvals in international markets.
- Pricing adjustments due to patent cliffs and biosimilar entries.
How Is the Regulatory Environment Shaping Pricing?
Regulatory agencies are increasingly scrutinizing pricing strategies, emphasizing value-based agreements. The U.S. FDA's accelerated approval pathway has facilitated earlier market entry but may lead to subsequent price renegotiations based on real-world effectiveness data.
International markets often impose price caps. For example, the European Union has negotiated lower prices for similar targeted therapies, and such trends impact negotiations for Tucatinib.
Final Insights
The market for NDC 42385-0945 remains modest but is anticipated to grow with pipeline expansion. Price points are relatively high, reflecting targeted therapy status and limited competition. Future pricing will be influenced by market dynamics, competition, and regulatory policies.
Key Takeaways
- NDC 42385-0945 (Tucatinib) is a targeted oral kinase inhibitor approved for HER2-positive metastatic breast cancer.
- Current annual sales are around $300 million, with a market share below 15% among HER2 therapies.
- Pricing ranges from $10,000 to $12,000 per treatment cycle, with stability expected short-term.
- Market projections suggest sales could reach $500 million by 2025, supported by expanding indications and combination regimens.
- Evolving regulatory and competitive landscapes will impact future pricing strategies and market share.
FAQs
1. What factors could lower the price of tucatinib?
Introduction of biosimilars, patent expiration, increased competition from alternative therapies, and value-based pricing agreements could reduce costs.
2. How does tucatinib's efficacy compare to other HER2-targeted drugs?
It provides benefits in HER2-positive metastatic breast cancer, especially after prior therapies, with response rates comparable or superior in some resistant cases.
3. Are there geographic regions with higher adoption?
Currently, US and European markets lead adoption. Emerging markets may see increased use pending regulatory approvals and pricing negotiations.
4. What are the main barriers to market growth?
Presence of well-established competitors, limited indications, and reimbursement challenges limit expansion prospects.
5. Will tucatinib's pricing strategy change with new data?
Positive trial results in early-stage disease or combination regimens could justify premium pricing, but negotiations with payers could enforce discounts.
Sources:
[1] FDA approval announcement, April 2020.
[2] IQVIA National Sales Perspectives, 2022.
[3] Market research reports on HER2-positive breast cancer therapeutics, 2022.
[4] Industry analysis, EvaluatePharma, 2022.
